| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, FE Davies, ... Blood, The Journal of the American Society of Hematology 132 (6), 587-597, 2018 | 432 | 2018 |
| A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, ... Leukemia 33 (1), 159-170, 2019 | 431 | 2019 |
| Genomic landscape and chronological reconstruction of driver events in multiple myeloma F Maura, N Bolli, N Angelopoulos, KJ Dawson, D Leongamornlert, ... Nature communications 10 (1), 3835, 2019 | 265 | 2019 |
| Genomic patterns of progression in smoldering multiple myeloma N Bolli, F Maura, S Minvielle, D Gloznik, R Szalat, A Fullam, ... Nature communications 9 (1), 3363, 2018 | 199 | 2018 |
| Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease C Cohen, B Royer, V Javaugue, R Szalat, K El Karoui, A Caulier, ... Kidney International 88 (5), 1135-1143, 2015 | 149 | 2015 |
| Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases S Harel, M Mohr, I Jahn, F Aucouturier, L Galicier, B Asli, M Malphettes, ... British journal of haematology 168 (5), 671-678, 2015 | 116 | 2015 |
| Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy R Szalat, B Arnulf, L Karlin, M Rybojad, B Asli, M Malphettes, L Galicier, ... Blood, The Journal of the American Society of Hematology 118 (14), 3777-3784, 2011 | 111 | 2011 |
| Prevalence and outcome of COVID-19 infection in cancer patients: a national Veterans Affairs study NR Fillmore, J La, RE Szalat, DP Tuck, V Nguyen, C Yildirim, NV Do, ... JNCI: Journal of the National Cancer Institute 113 (6), 691-698, 2021 | 103 | 2021 |
| Good syndrome: an adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications M Malphettes, L Gérard, L Galicier, D Boutboul, B Asli, R Szalat, A Perlat, ... Clinical Infectious Diseases 61 (2), e13-e19, 2015 | 103 | 2015 |
| Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines F Maura, M Petljak, M Lionetti, I Cifola, W Liang, E Pinatel, LB Alexandrov, ... Leukemia 32 (4), 1043-1047, 2018 | 102 | 2018 |
| Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in … X Leleu, G Fouquet, B Hebraud, M Roussel, D Caillot, ML Chrétien, ... Leukemia 27 (11), 2242-2244, 2013 | 76 | 2013 |
| A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications J Jakubikova, D Cholujova, T Hideshima, P Gronesova, A Soltysova, ... Oncotarget 7 (47), 77326, 2016 | 73 | 2016 |
| Gene expression profiles in myeloma: ready for the real world? R Szalat, H Avet-Loiseau, NC Munshi Clinical Cancer Research 22 (22), 5434-5442, 2016 | 67 | 2016 |
| Diagnosis of Castleman disease R Szalat, NC Munshi Hematology/Oncology Clinics 32 (1), 53-64, 2018 | 64 | 2018 |
| Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group MK Samur, A Aktas Samur, M Fulciniti, R Szalat, T Han, M Shammas, ... Journal of Clinical Oncology 38 (27), 3107-3118, 2020 | 55 | 2020 |
| Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma MK Samur, S Minvielle, A Gulla, M Fulciniti, A Cleynen, A Aktas Samur, ... Leukemia 32 (12), 2626-2635, 2018 | 53 | 2018 |
| Nucleotide excision repair is a potential therapeutic target in multiple myeloma R Szalat, MK Samur, M Fulciniti, M Lopez, P Nanjappa, A Cleynen, K Wen, ... Leukemia 32 (1), 111-119, 2018 | 47 | 2018 |
| Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma M Fulciniti, J Martinez-Lopez, W Senapedis, S Oliva, R Lakshmi Bandi, ... Blood, The Journal of the American Society of Hematology 129 (16), 2233-2245, 2017 | 47 | 2017 |
| Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy R Szalat, J Pirault, JP Fermand, A Carrié, F Saint‐Charles, M Olivier, ... Journal of Internal Medicine 276 (3), 269-284, 2014 | 39 | 2014 |
| Genomic heterogeneity in multiple myeloma R Szalat, NC Munshi Current opinion in genetics & development 30, 56-65, 2015 | 37 | 2015 |
